IPO Year:
Exchange: NASDAQ
Date | Price Target | Rating | Analyst |
---|
6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)
6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)
6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)
6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)
6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)
6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)
6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)
6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)
6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)
6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)
Shares of Urban Outfitters, Inc. (NASDAQ:URBN) rose sharply in today's pre-market trading after the company reported better-than-expected financial results for its first quarter on Tuesday. The company reported quarterly earnings of 69 cents per share, which beat the analyst consensus estimate of 52 cents. Quarterly sales clocked in at $1.2 billion, beating the analyst consensus estimate of $1.175 billion, according to data from Benzinga Pro. Urban Outfitters shares jumped 6.7% to $44.10 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers MGO Global, Inc. (NASDAQ:MGOL) gained 91.2% to $2.39 in pre-market trading. MGO Global shar
Trial's first and second cohorts maintaining signs of potential efficacy out to 24 weeksData from the second cohort showed improvements in eosinophil counts and histological scores out to 12 weeks suggesting a dose response over the first cohortData from the trial's third cohort suggest improvements in patient-reported symptoms and histological outcomes at 12 weeksEP-104GI showed an encouraging safety profile in all three cohorts
Consistent improvement in patient reported outcomes with 10 of 11 evaluable patients in the first four cohorts experiencing a reduction in symptom (SDI1) scores at 12 weeksThe fourth cohort showed the greatest percentage change in histology (EoEHSS2) scores of any cohort to dateThe RESOLVE Phase 1b/2a trial is progressing as anticipated with no serious adverse events reported in all four fully-dosed cohortsVICTORIA, BC, Sept. 11, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX:EPRX) (NASDAQ:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need
VICTORIA, BC, Sept. 4, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX:EPRX) (NASDAQ:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company will be presenting at the upcoming H.C. Wainwright 26th Annual Global Investment Conference being held in New York, NY from September 9-11, 2024. Presentation Details: The Company's presentation is at 8:00 a.m. ET on Monday, September 9, 2024. Eupraxia invite
VICTORIA, BC, Aug. 7, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2024. All dollar values are in U.S. dollars unless stated otherwise. "Our eosinophilic esophagitis ("EoE") clinical program is making excellent progress, as additional safety and efficacy data from our ongoing RESOLVE study conti
The Company also provides an update on the Silicon Valley Bank convertible debt facilityIncluding the new C$12 million convertible debt facility, Eupraxia anticipates it has sufficient cash to fund its operations to the second quarter of 2025VICTORIA, BC, Aug. 2, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX:EPRX) (NASDAQ:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced entry into a new C$12 million convertible debt facility (the "Convertible Debt Facility").
VICTORIA, BC, July 8, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX:EPRX) (NASDAQ:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company's Chief Operating and Scientific Officer, Dr. Amanda Malone, will be presenting at the upcoming Controlled Release Society 2024 Annual Meeting and Expo being held in Bologna, Italy from July 8-12, 2024. Presentation Details: Abstract ID: 4085079 Presentation Title: EP-104, a novel microparticle formulation achieving extended-release of flut
Osteoarthritis ("OA") is the leading cause of disability in older adults.The U.S. Centers for Disease Control and Prevention estimates that knee OA affects more than 30 million people in the U.S. alone.Registration for the webinar now open to the public.VICTORIA, BC, July 3, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX:EPRX) (NASDAQ:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that Eupraxia's CEO, Dr. James A. Helliwell, will present at a Tribe Public Webinar Presentation and Q&A Event titled, "Exploring The Rapid
VICTORIA, BC, June 6, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX:EPRX) (NASDAQ:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, is pleased to announce the results from its Annual General and Special Meeting of Shareholders (the "Meeting") held on June 6, 2024. Pursuant to a resolution passed by ballot vote, all of the six nominees proposed by management for election to the Company's board of directors (the "Board") at the Meeting and listed in the Company's Management Information Circular dated May 1, 2024, were elected. The direct
VICTORIA, BC, June 5, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX:EPRX) (NASDAQ:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that results from its Phase 2 study of EP-104IAR for the treatment of osteoarthritis of the knee will be presented at the upcoming European Alliance of Associations for Rheumatology ("EULAR") European Congress of Rheumatology 2024 (the "Meeting"). The EULAR Meeting is being held in Vienna, Austria from June 12-15, 2024. Presentation Details: Programme No.: OP0274 Presentation Title: Effi
Eight of nine patients responding to the treatment, plus the encouraging safety data observed in the RESOLVE Phase 1b/2a trial of EP-104GI, provided the catalyst for the trial expansionEarly low-dose cohorts showing meaningful improvement in patient symptoms and biological evidence of diseaseTrial expansion allows more patients to be treated at higher doses and followed for up to 52 weeks, up from 24 weeksVICTORIA, BC, May 23, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX:EPRX) (NASDAQ:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, t
VICTORIA, BC, May 22, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX:EPRX) (NASDAQ:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that it will host a virtual key opinion leader ("KOL") event on Wednesday, May 29, 2024, at 10:00 AM ET. To register, please click here. The event will feature Evan S. Dellon, MD, MPH (University of North Carolina School of Medicine) who will join Company management to discuss the unmet medical need and current treatment landscape for EoE. Dr. Dellon is Chairman of the Company's Gastrointes
VICTORIA, BC, Aug. 7, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2024. All dollar values are in U.S. dollars unless stated otherwise. "Our eosinophilic esophagitis ("EoE") clinical program is making excellent progress, as additional safety and efficacy data from our ongoing RESOLVE study conti